united states – Page 6 – Retraction Watch

OSU cancer researcher Carlo Croce loses appeal of New York Times libel suit

Carlo Croce, a prolific cancer researcher at The Ohio State University (OSU) in Columbus who was the subject of a 2017 front page story in The New York Times about allegations of misconduct against him, has lost a libel suit that he filed against the newspaper.

As first reported by Courthouse News Service earlier this week, the Sixth Circuit upheld a lower court’s November 2018 ruling tossing most of Croce’s claims. In the ruling, U.S. Circuit Judge Karen Moore writes:

Criminologist posts 27-page article explaining why he asked for one of his papers to be retracted

On Sunday, May 5 of this year, Justin Pickett received an email from a “John Smith” with the subject line “Data irregularities and request for data.”

“There seem to be irregularities in the data and findings in five articles that you published together with two surveys,” the anonymous correspondent wrote. “This document outlines those irregularities.”

Pickett was a co-author on only one of the papers, “Ethnic threat and social control: Examining public support for judicial use of ethnicity in punishment,” which was published in 2011 — the year he earned his PhD from Florida State University (FSU) — in the journal Criminology. The other four papers were published from 2015 to 2019 in Criminology, Law & Society Review, and Social Problems. The only author common to all four was Eric A. Stewart, a professor at FSU.

Georgia State researcher has two papers retracted, eight flagged. He’s not happy about it.

The Journal of Biological Chemistry has retracted two papers by a Georgia State University researcher, as well as flagged eight more with expressions of concern, a move the scientist called “unfair and unjustified.”

Ming-Hui Zou, the common author on all ten papers — as well as on two more that have been corrected by the same journal — is, according to Georgia State,

an internationally recognized researcher in molecular and translational medicine and a Georgia Research Alliance Eminent Scholar in Molecular Medicine and associate vice president for research at Georgia State University…

Zou was at the University of Oklahoma when the papers in question were published. He moved to Georgia State in 2015.

Here’s the retraction notice for “Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo,” published in 2008 Zou as the last author:

A university requested retractions of eight papers. It took journals a year to yank four of them.

On March 30, 2018, The Ohio State University (OSU) released a 75-page report concluding that Ching-Shih Chen, a cancer researcher, had deviated “from the accepted practices of image handling and figure generation and intentionally falsifying data.” The report recommended the retraction of eight papers.

By the end of August of 2018, Chen had had four papers retracted — one in Cancer Research, two in the Journal of Medicinal Chemistry, and one in PLoS ONE.

But it wasn’t until more than a year after the report was released that the other four papers — two from Carcinogenesis, one from Clinical Cancer Research, and one from Molecular Cellular Therapeutics — were retracted, all between April 1 and May 1 of this year.

What took so long? Your guess is as good as ours; none of the editors of those journals responded to our requests for comment.

Harvard cancer lab subject to federal misconduct probe

Sam W. Lee, a Harvard researcher — or perhaps former Harvard researcher — who has lost three papers to retraction, including one from Nature, now has an expression of concern for another article, this one in Molecular and Cellular Biology.

The notice for that paper, 2000’s “Overexpression of Kinase-Associated Phosphatase (KAP) in Breast and Prostate Cancer and Inhibition of the Transformed Phenotype by Antisense KAP Expression,” reads: Continue reading Harvard cancer lab subject to federal misconduct probe

Joseph Thomas just earned $33.8 million in a $112.5 million settlement with Duke. Here’s his story.

Tomorrow is Joe Thomas’s 35th birthday. And earlier this week, he received quite a birthday present, even if it wasn’t intended that way: Thomas earned a $33.75 million payout from a lawsuit he filed against Duke University six years ago.

As Retraction Watch readers may recall, Thomas was the whistleblower in a case alleging scientific misconduct that Duke settled yesterday for $112.5 million. Our Ivan Oransky has an exclusive profile of him — including how he “celebrated” the settlement — at Medscape. Continue reading Joseph Thomas just earned $33.8 million in a $112.5 million settlement with Duke. Here’s his story.

Duke settles case alleging data doctoring for $112.5 million

Retraction Watch readers may recall the name Erin Potts-Kant. We’ve been reporting on retractions by Potts-Kant, a former lab tech at Duke, since 2013. (The count is now 17.) Along the way, we learned that she had been convicted of embezzlement, but that there was a bigger story: There was a False Claims Act case against Duke, Potts-Kant, and Michael Foster, in whose lab she worked, alleging that the university had known that faked data had been included in grant applications.

The case has now settled, for what Duke acknowledges is a “substantial” sum of $112.5 million. That means the whistleblower, another former lab tech, will earn more than $30 million. For details, head over to Ivan’s story on Medscape. Continue reading Duke settles case alleging data doctoring for $112.5 million

Eyes wide shut at vision journal as retraction notice misses the point

Molecular Vision appears to have been flying blind when it retracted a 2013 paper by Rajendra Kadam and colleagues.

In December 2018, Kadam, a former “golden boy” in pharmaceutical research at the University of Colorado, Denver, was the subject of a finding from the U.S. Office of Research Integrity, which stated that he had fabricated his data. As part of the agreement, Kadam agreed to retract a paper in Molecular Vision. .

Kadam, who in 2016 had his doctoral degree revoked by UC Denver, two years after the university completed an investigation and sent its finding to the Office of Research Integrity (ORI), now has eight retractions, two expressions of concern and a correction. Seven of them mention fabrication of data. But Molecular Vision, the most recent addition to the list, does not.

The paper was titled “Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes.” Its retraction notice, issued February 18, states: Continue reading Eyes wide shut at vision journal as retraction notice misses the point

A university thought its misconduct investigation was complete. Then a PubPeer comment appeared.

When Venkata Sudheer Kumar Ramadugu, then a postdoc at the University of Michigan, admitted to the university on June 28 of last year that he had committed research misconduct in a paper that appeared in Chemical Communications in 2017, he also “attested that he did not manipulate any data in his other four co-authored publications published while at the University of Michigan.”

And so, a few days later, Michael J. Imperiale, the university’s research integrity officer, wrote a letter to the U.S. Office of Research Integrity (ORI) informing them of the findings. On August 2, Ramadagu was terminated from Michigan. And on August 3, Ayyalusamy Ramamoorthy, the head of the lab where Ramadagu had worked, wrote a letter to Chemical Communications requesting retraction of the paper.

While the retraction would not appear until the end of November, and ORI sanctions not announced until the end of December, Michigan’s responsibilities seemed to have been discharged as of early August. But documents obtained by Retraction Watch through a public records request detail how that was not the end of the story. Continue reading A university thought its misconduct investigation was complete. Then a PubPeer comment appeared.

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: